查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2088939

藥物和基因遞送裝置市場：按技術、裝置類型、分子類型、最終用戶、應用和治療領域分類——2026-2032年全球市場預測

Drug & Gene Delivery Devices Market by Technology, Device Type, Molecule Type, End User, Application, Therapeutic Area - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 186 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，藥物和基因輸送設備市場將成長至 40.5 億美元，複合年成長率為 9.29%。

主要市場統計數據
基準年 2025 21.7億美元
預計年份：2026年 23.7億美元
預測年份 2032 40.5億美元
複合年成長率 (%) 9.29%

藥物和基因遞送裝置的引入

藥物和基因遞送裝置是快速發展的治療生態系統的核心，它將先進的生物製藥、精準醫療、疫苗以及細胞和基因療法以臨床可控、擴充性且方便用戶使用的方式與患者連接起來。此類別包括自動注射器、穿戴式注射器、輸液幫浦、吸入系統、植入式遞送平台、微針、病毒載體遞送、非病毒載體、脂質奈米顆粒、電穿孔系統以及其他能夠提高給藥準確性、依從性、穩定性和患者可及性的基礎技術。

一場變革性的變革，重塑了管理平台。

藥物給藥方式正從以醫院為中心的模式轉向以病人為中心、網路化和微創的方式。預填充式注射器、自動注射器、穿戴式注射器、智慧型幫浦和數位化用藥依從性支援工具正推動更多療法進入門診和居家照護環境。同時，高黏度、高劑量生物製藥的出現也加速了穿戴式和高壓注射系統的創新。

人工智慧（AI）的累積影響

人工智慧 (AI) 正成為藥物和基因遞送裝置整個生命週期中一股切實可行的驅動力。在藥物發現和製劑開發階段，AI 模型可輔助進行輔料篩檢、奈米顆粒行為預測、蛋白質穩定性評估和載體設計最佳化。在裝置設計領域，機器學習支援模擬主導設計、失效模式分析、人體工學測試和預測性品管，這些方法經過可靠的實驗數據檢驗後，可顯著縮短開發週期。

全球市場的關鍵區域洞察

亞太地區正崛起為藥物和基因遞送裝置技術的關鍵區域，這主要得益於生物製藥研發管線的不斷擴展、政府對生物技術的投入、龐大的患者群體以及對自我給藥療法日益成長的需求。儘管中國、日本、韓國、印度和澳洲等國在先進療法的臨床研究、在地化生產和法規核准流程方面都在不斷完善，但該地區對成本的關注仍然促使人們傾向於擴充性、可靠且成本績效的遞送平台。

策略擴張的關鍵集團洞察

隨著醫療旅遊、本地藥品生產以及跨區域監管協調工作的開展，注射劑、疫苗、生物相似藥和專科療法的可及性日益提高，東協市場的重要性也日益凸顯。我們集團致力於滿足市場對實用、經濟高效的給藥裝置的需求，這些裝置能夠在各種醫療環境、潮濕氣候和分散式醫療機構中可靠運作。

來自主要國家關於藥物和基因遞送裝置的見解

美國憑藉其FDA監管路徑、先進的臨床試驗網路和雄厚的專科藥物支出，在藥物輸送裝置創新、複合產品核准、連線健診應用和基因療法商業化方面處於主導地位。加拿大擁有穩定的法規環境、透過公共醫療體系建立的採購機制以及不斷擴大的生物製藥應用，而墨西哥則在醫療技術產品製造和區域供應鏈方面不斷加強自身作用。巴西仍然擁有拉丁美洲最大的醫療保健系統，在生物相似藥、疫苗和符合公共和私人支付方需求的注射療法方面存在著許多機會。

為行業領導者提供的實用建議

產業領導者應優先考慮以病人為中心的設計、檢驗的人因工程以及貫穿醫療設備和治療方案研發全生命週期的質量，從早期階段開始就應如此。對於藥物傳遞裝置，設計應考慮劑量精準性、減輕疼痛、可靠運作、易於操作、在臨床需要時具備連接性以及與高黏度生技藥品的兼容性。對於基因遞送系統，投資應著重於載體最佳化、標靶遞送、可擴展的分析以及能夠降低變異性並提高製程穩定性的生產平台。

調查方法和資料檢驗

本執行摘要基於二手檢驗，採用公開可查的資料，包括監管出版刊物、臨床試驗註冊資訊、同行評審文獻、專利資料庫、衛生政策文件、藥物安全監測資料以及國際衛生和貿易資料集。主要參考文獻包括美國食品藥物資訊來源(FDA) 和歐洲藥品管理局 (EMA) 關於聯合用藥和先進療法的指南、世界衛生組織 (WHO) 關於疫苗和獲取途徑的資料，以及世界銀行、經合組織 (OECD) 和各國衛生機構等組織提供的經認可的公共數據。

結論：管理方法創新是一種競爭優勢

藥物和基因遞送裝置領域正進入一個新階段，在這個階段，療法創新、裝置易用性、數位化智慧和卓越的製造能力密不可分。隨著生物製藥、mRNA平台以及細胞和基因療法的不斷發展，遞送技術將決定先進藥物能否有效率、大規模地惠及病患。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章 藥物與基因傳遞裝置市場：依技術分類

  • 水凝膠基底
  • 脂質體型
  • 奈米顆粒
  • 聚合物體系

第8章 藥物與基因遞送裝置市場：依裝置類型分類

  • 自動噴油器
  • 點滴幫浦
  • 無針注射器
  • 筆式注射器
  • 注射器

第9章：藥物與基因遞送裝置市場：依分子類型分類

  • 生物製劑
    • 單株抗體
    • 胜肽
    • 重組蛋白
  • 基因治療
    • 非病毒
      • 基於脂質的
      • 聚合物體系
    • 病毒載體
      • 腺病毒
      • 慢病毒
      • 逆轉錄病毒
  • 低分子

第10章 藥物與基因遞送設備市場：依最終用戶分類

  • 診所
  • 家庭醫療保健
  • 醫院
  • 研究所

第11章 藥物與基因傳遞裝置市場：依應用領域分類

  • 控釋
  • 智慧配送
  • 緩釋型
  • 精準投放

第12章 藥物與基因遞送裝置市場：依治療領域分類

  • 心血管系統
  • 糖尿病
  • 感染疾病
  • 腫瘤學

第13章 藥物與基因遞送設備市場：按地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第14章 藥物與基因遞送設備市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 藥物與基因遞送設備市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第17章：公司簡介

  • Abbott Laboratories
  • AptarGroup, Inc.
  • Bausch+Lomb Incorporated
  • Baxter International Inc.
  • Becton, Dickinson and Company
  • Camurus AB
  • Cook Medical LLC
  • Elixir Medical Corporation
  • Enable Injections, Inc.
  • Gerresheimer AG
  • Haselmeier GmbH
  • Insulet Corporation
  • Medtronic plc
  • Nipro Corporation
  • Owen Mumford Limited
  • Phillips-Medisize, LLC
  • Santen Pharmaceutical Co., Ltd.
  • SCHOTT Pharma AG & Co. KGaA
  • SHL Medical AG
  • Spectrum Plastics Group
  • Stevanato Group SpA
  • Tandem Diabetes Care, Inc.
  • Teleflex Incorporated
  • Terumo Corporation
  • West Pharmaceutical Services, Inc.
  • Ypsomed Holding AG
Product Code: MRR-A86604082727

The Drug & Gene Delivery Devices Market is projected to grow by USD 4.05 billion at a CAGR of 9.29% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 2.17 billion
Estimated Year [2026] USD 2.37 billion
Forecast Year [2032] USD 4.05 billion
CAGR (%) 9.29%

Drug & Gene Delivery Devices Introduction

Drug and gene delivery devices sit at the center of a rapidly evolving therapeutic ecosystem, connecting advanced biologics, precision medicines, vaccines, and cell and gene therapies with patients in clinically controlled, scalable, and user-friendly formats. The category spans autoinjectors, wearable injectors, infusion pumps, inhalation systems, implantable delivery platforms, microneedles, viral vector delivery, non-viral vectors, lipid nanoparticles, electroporation systems, and other enabling technologies that improve dosing accuracy, adherence, stability, and patient access.

Demand is being shaped by the growth of chronic disease management, biologic drug launches, home-based care, specialty pharmaceuticals, and the clinical expansion of gene therapies. Regulatory agencies such as the U.S. FDA and European Medicines Agency continue to emphasize combination-product quality, human factors engineering, device reliability, sterility assurance, and post-market safety, making validated device design and evidence-based delivery performance key differentiators across the drug delivery devices and gene delivery systems landscape.

Transformative Shifts Reshaping Delivery Platforms

The landscape is shifting from hospital-centered administration toward connected, patient-centric, and minimally invasive delivery. Prefilled syringes, autoinjectors, on-body injectors, smart pumps, and digital adherence tools are enabling more therapies to move into outpatient and home-care settings, while biologics with higher viscosities and larger dose volumes are accelerating innovation in wearable and high-force injection systems.

In gene delivery, the industry is moving beyond a reliance on established viral vectors toward optimized adeno-associated virus platforms, lentiviral systems, lipid nanoparticles, polymeric carriers, and targeted non-viral delivery. These shifts are supported by advances in genomic medicine, mRNA technology, payload engineering, and manufacturing analytics, but they also increase the need for scalable production, cold-chain resilience, immunogenicity management, and regulatory-grade characterization.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is becoming a practical accelerator across the drug and gene delivery device lifecycle. In discovery and formulation, AI models help screen excipients, predict nanoparticle behavior, evaluate protein stability, and optimize vector design. In device engineering, machine learning supports simulation-led design, failure-mode analysis, human factors testing, and predictive quality controls that can shorten development cycles when validated against robust experimental data.

AI is also strengthening manufacturing and post-market performance. Computer vision, sensor analytics, and predictive maintenance improve process control for sterile fill-finish, vector production, assembly, and packaging, while real-world data analytics can identify adherence patterns, infusion anomalies, and safety signals. The strongest opportunities are emerging where AI is governed by traceable data, explainable validation, cybersecurity controls, and compliance with evolving FDA, EMA, and international expectations for software, connected devices, and quality management systems.

Key Regional Insights Across Global Markets

Asia-Pacific is advancing as a major region for drug delivery devices and gene delivery technologies due to expanding biologics pipelines, government investment in biotechnology, large patient populations, and rising demand for self-administered therapies. China, Japan, South Korea, India, and Australia are strengthening clinical research, local manufacturing, and regulatory pathways for advanced therapies, while regional cost sensitivity continues to favor scalable, reliable, and value-engineered delivery platforms.

North America remains a leading innovation and commercialization hub, supported by FDA-cleared combination products, advanced biomanufacturing, clinical trial infrastructure, and a large specialty-pharmaceutical ecosystem. Europe benefits from the European Medicines Agency framework, established medtech clusters, strong biosimilar adoption, and advanced therapy medicinal product regulation, while Latin America is advancing through private healthcare expansion, vaccine infrastructure, and gradual adoption of specialty injectable therapies across Brazil, Mexico, and other major healthcare systems.

The Middle East is investing in healthcare modernization, specialty care, medical infrastructure, and localization strategies, particularly in Gulf markets, while Africa presents long-term potential linked to vaccination programs, infectious disease control, and improving cold-chain and primary-care infrastructure. Across all regions, successful market entry depends on regulatory readiness, payer evidence, device usability, temperature-controlled logistics, and partnerships that align innovative delivery technologies with local healthcare delivery models.

Key Group Insights for Strategic Expansion

ASEAN markets are gaining importance as medical tourism, local pharmaceutical production, and regional harmonization efforts improve access to injectable drugs, vaccines, biosimilars, and specialty therapies. The group offers demand for practical, cost-efficient drug delivery devices that can perform reliably in diverse healthcare settings, humid climates, and decentralized care environments.

The GCC is prioritizing healthcare transformation, domestic life sciences investment, and advanced hospital infrastructure, creating opportunities for premium drug delivery devices, connected adherence solutions, and specialty therapy platforms. The European Union remains a regulatory and innovation anchor for combination products and advanced therapy medicinal products, with medical device regulation, pharmacovigilance expectations, data protection rules, and sustainability policy influencing device design, packaging, traceability, and lifecycle management.

BRICS countries combine large patient bases with rising biologics manufacturing capacity and growing public investment in biotechnology, making affordability, technology transfer, local production, and scalable quality systems central to adoption. G7 markets continue to set quality, reimbursement, intellectual property, and clinical-evidence benchmarks for high-value drug and gene delivery platforms, while NATO countries' focus on medical readiness and secure supply chains reinforces demand for resilient manufacturing, stockpiling capabilities, cybersecurity, and dependable injectable and vaccine delivery systems.

Key Country Insights in Drug & Gene Delivery Devices

The United States leads in drug delivery device innovation, combination-product approvals, connected health adoption, and gene therapy commercialization, supported by FDA regulatory pathways, advanced clinical trial networks, and strong specialty pharmaceutical spending. Canada offers a stable regulatory environment, public health system purchasing discipline, and growing biologics adoption, while Mexico is strengthening its role in medtech manufacturing and regional supply chains. Brazil remains Latin America's largest healthcare system, with opportunities tied to biosimilars, vaccines, and injectable therapies that meet public and private payer requirements.

In Europe, the United Kingdom supports life sciences innovation through strong academic and clinical infrastructure, while Germany remains a major medtech and biopharma manufacturing center. France combines advanced hospital networks with public investment in biotechnology, and Italy and Spain contribute established pharmaceutical manufacturing, clinical research, and specialty-care demand. Russia has maintained interest in domestic pharmaceutical production and vaccine platforms, though market access, regulatory navigation, and supply-chain planning require careful risk assessment.

China is scaling biomanufacturing, clinical development, and domestic innovation in biologics and gene delivery, while India is expanding vaccine, biosimilar, and cost-efficient device capabilities. Japan's mature regulatory system and aging population support demand for safe, easy-to-use delivery devices, and South Korea is advancing through biologics manufacturing, digital health, and cell and gene therapy research. Australia provides a strong clinical trial environment, transparent regulation, and demand for high-quality delivery systems across chronic disease and specialty-care applications.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize patient-centric engineering, validated human factors, and lifecycle quality from the earliest stages of device and therapy development. For drug delivery devices, this means designing for dose accuracy, reduced pain, reliable activation, intuitive training, connectivity where clinically useful, and compatibility with high-viscosity biologics. For gene delivery systems, leaders should invest in vector optimization, targeted delivery, scalable analytics, and manufacturing platforms that reduce variability and improve process robustness.

Commercial success will depend on integrated evidence strategies that combine clinical outcomes, usability data, pharmacoeconomic value, and real-world performance. Companies should build regional regulatory intelligence, diversify suppliers for critical components, strengthen cold-chain and sterile manufacturing resilience, and pursue partnerships with biopharma developers, contract development and manufacturing organizations, digital health firms, and healthcare providers to accelerate adoption while maintaining compliance.

Research Methodology and Data Validation

This executive summary is built on a secondary-research framework using publicly available and verifiable sources such as regulatory agency publications, clinical trial registries, peer-reviewed literature, patent databases, healthcare policy documents, pharmacovigilance materials, and international health and trade datasets. Key reference points include FDA and EMA guidance on combination products and advanced therapies, WHO materials on vaccines and access, and recognized public data from organizations such as the World Bank, OECD, and national health agencies.

Insights are synthesized through triangulation across technology trends, regulatory developments, regional healthcare infrastructure, product commercialization patterns, and manufacturing dynamics. The methodology emphasizes data consistency, source credibility, recency, and practical relevance for decision-makers in drug delivery devices, gene delivery technologies, biopharmaceutical manufacturing, medtech investment, and healthcare strategy.

Conclusion: Delivery Innovation as a Competitive Advantage

The drug and gene delivery devices landscape is entering a phase where therapeutic innovation, device usability, digital intelligence, and manufacturing excellence are inseparable. As biologics, mRNA platforms, and cell and gene therapies expand, delivery technologies will determine how effectively advanced medicines reach patients at scale.

Organizations that combine regulatory-grade evidence, patient-centered design, AI-enabled quality systems, resilient supply chains, and region-specific commercialization strategies will be best positioned to create sustainable value. The next competitive advantage will come not only from novel therapies, but from delivery platforms that make those therapies safer, more accessible, more reliable, and more economically sustainable.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Drug & Gene Delivery Devices Market, by Technology

  • 7.1. Hydrogel Based
  • 7.2. Liposomal
  • 7.3. Nanoparticle
  • 7.4. Polymer Based

8. Drug & Gene Delivery Devices Market, by Device Type

  • 8.1. Auto Injector
  • 8.2. Infusion Pump
  • 8.3. Needle Free Injector
  • 8.4. Pen Injector
  • 8.5. Syringe

9. Drug & Gene Delivery Devices Market, by Molecule Type

  • 9.1. Biologic
    • 9.1.1. Monoclonal Antibody
    • 9.1.2. Peptide
    • 9.1.3. Recombinant Protein
  • 9.2. Gene Therapy
    • 9.2.1. Non Viral
      • 9.2.1.1. Lipid Based
      • 9.2.1.2. Polymer Based
    • 9.2.2. Viral Vector
      • 9.2.2.1. Adenoviral
      • 9.2.2.2. Lentiviral
      • 9.2.2.3. Retroviral
  • 9.3. Small Molecule

10. Drug & Gene Delivery Devices Market, by End User

  • 10.1. Clinics
  • 10.2. Home Healthcare
  • 10.3. Hospitals
  • 10.4. Research Laboratories

11. Drug & Gene Delivery Devices Market, by Application

  • 11.1. Controlled Release
  • 11.2. Smart Delivery
  • 11.3. Sustained Release
  • 11.4. Targeted Delivery

12. Drug & Gene Delivery Devices Market, by Therapeutic Area

  • 12.1. Cardiovascular
  • 12.2. Diabetes
  • 12.3. Infectious Diseases
  • 12.4. Oncology

13. Drug & Gene Delivery Devices Market, by Region

  • 13.1. Asia-Pacific
  • 13.2. North America
  • 13.3. Latin America
  • 13.4. Europe
  • 13.5. Middle East
  • 13.6. Africa

14. Drug & Gene Delivery Devices Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Drug & Gene Delivery Devices Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Concentration Analysis, 2025
    • 16.1.1. Concentration Ratio (CR)
    • 16.1.2. Herfindahl Hirschman Index (HHI)
  • 16.2. Recent Developments & Impact Analysis, 2025
  • 16.3. Product Portfolio Analysis, 2025
  • 16.4. Benchmarking Analysis, 2025

17. Company Profiles

  • 17.1. Abbott Laboratories
  • 17.2. AptarGroup, Inc.
  • 17.3. Bausch + Lomb Incorporated
  • 17.4. Baxter International Inc.
  • 17.5. Becton, Dickinson and Company
  • 17.6. Camurus AB
  • 17.7. Cook Medical LLC
  • 17.8. Elixir Medical Corporation
  • 17.9. Enable Injections, Inc.
  • 17.10. Gerresheimer AG
  • 17.11. Haselmeier GmbH
  • 17.12. Insulet Corporation
  • 17.13. Medtronic plc
  • 17.14. Nipro Corporation
  • 17.15. Owen Mumford Limited
  • 17.16. Phillips-Medisize, LLC
  • 17.17. Santen Pharmaceutical Co., Ltd.
  • 17.18. SCHOTT Pharma AG & Co. KGaA
  • 17.19. SHL Medical AG
  • 17.20. Spectrum Plastics Group
  • 17.21. Stevanato Group S.p.A.
  • 17.22. Tandem Diabetes Care, Inc.
  • 17.23. Teleflex Incorporated
  • 17.24. Terumo Corporation
  • 17.25. West Pharmaceutical Services, Inc.
  • 17.26. Ypsomed Holding AG

LIST OF FIGURES

  • FIGURE 1. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 7. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 8. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY TECHNOLOGY, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY MOLECULE TYPE, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY MOLECULE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY END USER, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY APPLICATION, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY THERAPEUTIC AREA, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY THERAPEUTIC AREA, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 23. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 24. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 25. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL HYDROGEL BASED MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL HYDROGEL BASED MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL HYDROGEL BASED MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL LIPOSOMAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL LIPOSOMAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL LIPOSOMAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL NANOPARTICLE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL NANOPARTICLE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL NANOPARTICLE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL POLYMER BASED MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL POLYMER BASED MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL POLYMER BASED MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL AUTO INJECTOR MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL AUTO INJECTOR MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL AUTO INJECTOR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL INFUSION PUMP MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL INFUSION PUMP MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL INFUSION PUMP MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL NEEDLE FREE INJECTOR MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL NEEDLE FREE INJECTOR MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL NEEDLE FREE INJECTOR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL PEN INJECTOR MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL PEN INJECTOR MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL PEN INJECTOR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL SYRINGE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL SYRINGE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL SYRINGE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL BIOLOGIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL BIOLOGIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL BIOLOGIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL MONOCLONAL ANTIBODY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL MONOCLONAL ANTIBODY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL MONOCLONAL ANTIBODY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL PEPTIDE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL PEPTIDE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL PEPTIDE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL RECOMBINANT PROTEIN MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL RECOMBINANT PROTEIN MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL RECOMBINANT PROTEIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL GENE THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL GENE THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL GENE THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL NON VIRAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL NON VIRAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL NON VIRAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL LIPID BASED MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL LIPID BASED MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL LIPID BASED MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL POLYMER BASED MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL POLYMER BASED MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL POLYMER BASED MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL VIRAL VECTOR MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL VIRAL VECTOR MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL VIRAL VECTOR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL ADENOVIRAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL ADENOVIRAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL ADENOVIRAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL LENTIVIRAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL LENTIVIRAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL LENTIVIRAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL RETROVIRAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL RETROVIRAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL RETROVIRAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL SMALL MOLECULE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL SMALL MOLECULE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL SMALL MOLECULE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL HOME HEALTHCARE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL HOME HEALTHCARE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL HOME HEALTHCARE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL RESEARCH LABORATORIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL RESEARCH LABORATORIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL RESEARCH LABORATORIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL CONTROLLED RELEASE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL CONTROLLED RELEASE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL CONTROLLED RELEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL SMART DELIVERY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL SMART DELIVERY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL SMART DELIVERY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL SUSTAINED RELEASE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL SUSTAINED RELEASE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL SUSTAINED RELEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL TARGETED DELIVERY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL TARGETED DELIVERY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL TARGETED DELIVERY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL CARDIOVASCULAR MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL CARDIOVASCULAR MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL CARDIOVASCULAR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL DIABETES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL DIABETES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL DIABETES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL INFECTIOUS DISEASES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL INFECTIOUS DISEASES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL INFECTIOUS DISEASES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL ONCOLOGY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL ONCOLOGY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL ONCOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 111. ASIA-PACIFIC DRUG & GENE DELIVERY DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 112. ASIA-PACIFIC DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 113. ASIA-PACIFIC DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 114. ASIA-PACIFIC DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 115. ASIA-PACIFIC DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY BIOLOGIC, 2018-2032 (USD MILLION)
  • TABLE 116. ASIA-PACIFIC DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 117. ASIA-PACIFIC DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY NON VIRAL, 2018-2032 (USD MILLION)
  • TABLE 118. ASIA-PACIFIC DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 119. ASIA-PACIFIC DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 120. ASIA-PACIFIC DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 121. ASIA-PACIFIC DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 122. NORTH AMERICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 123. NORTH AMERICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 124. NORTH AMERICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 125. NORTH AMERICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 126. NORTH AMERICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY BIOLOGIC, 2018-2032 (USD MILLION)
  • TABLE 127. NORTH AMERICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 128. NORTH AMERICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY NON VIRAL, 2018-2032 (USD MILLION)
  • TABLE 129. NORTH AMERICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 130. NORTH AMERICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 131. NORTH AMERICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 132. NORTH AMERICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 133. LATIN AMERICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 134. LATIN AMERICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 135. LATIN AMERICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 136. LATIN AMERICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 137. LATIN AMERICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY BIOLOGIC, 2018-2032 (USD MILLION)
  • TABLE 138. LATIN AMERICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 139. LATIN AMERICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY NON VIRAL, 2018-2032 (USD MILLION)
  • TABLE 140. LATIN AMERICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 141. LATIN AMERICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 142. LATIN AMERICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 143. LATIN AMERICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPE DRUG & GENE DELIVERY DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPE DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPE DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPE DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPE DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY BIOLOGIC, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPE DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPE DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY NON VIRAL, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPE DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPE DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 153. EUROPE DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPE DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 155. MIDDLE EAST DRUG & GENE DELIVERY DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 156. MIDDLE EAST DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 157. MIDDLE EAST DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 158. MIDDLE EAST DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 159. MIDDLE EAST DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY BIOLOGIC, 2018-2032 (USD MILLION)
  • TABLE 160. MIDDLE EAST DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 161. MIDDLE EAST DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY NON VIRAL, 2018-2032 (USD MILLION)
  • TABLE 162. MIDDLE EAST DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 163. MIDDLE EAST DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 164. MIDDLE EAST DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 165. MIDDLE EAST DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 166. AFRICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 167. AFRICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 168. AFRICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 169. AFRICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 170. AFRICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY BIOLOGIC, 2018-2032 (USD MILLION)
  • TABLE 171. AFRICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 172. AFRICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY NON VIRAL, 2018-2032 (USD MILLION)
  • TABLE 173. AFRICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 174. AFRICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 175. AFRICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 176. AFRICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 177. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 178. ASEAN DRUG & GENE DELIVERY DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 179. ASEAN DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 180. ASEAN DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 181. ASEAN DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 182. ASEAN DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY BIOLOGIC, 2018-2032 (USD MILLION)
  • TABLE 183. ASEAN DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 184. ASEAN DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY NON VIRAL, 2018-2032 (USD MILLION)
  • TABLE 185. ASEAN DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 186. ASEAN DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 187. ASEAN DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 188. ASEAN DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 189. GCC DRUG & GENE DELIVERY DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 190. GCC DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 191. GCC DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 192. GCC DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 193. GCC DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY BIOLOGIC, 2018-2032 (USD MILLION)
  • TABLE 194. GCC DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 195. GCC DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY NON VIRAL, 2018-2032 (USD MILLION)
  • TABLE 196. GCC DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 197. GCC DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 198. GCC DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 199. GCC DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 200. EUROPEAN UNION DRUG & GENE DELIVERY DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 201. EUROPEAN UNION DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 202. EUROPEAN UNION DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 203. EUROPEAN UNION DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 204. EUROPEAN UNION DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY BIOLOGIC, 2018-2032 (USD MILLION)
  • TABLE 205. EUROPEAN UNION DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 206. EUROPEAN UNION DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY NON VIRAL, 2018-2032 (USD MILLION)
  • TABLE 207. EUROPEAN UNION DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 208. EUROPEAN UNION DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 209. EUROPEAN UNION DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 210. EUROPEAN UNION DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 211. BRICS DRUG & GENE DELIVERY DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 212. BRICS DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 213. BRICS DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 214. BRICS DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 215. BRICS DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY BIOLOGIC, 2018-2032 (USD MILLION)
  • TABLE 216. BRICS DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 217. BRICS DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY NON VIRAL, 2018-2032 (USD MILLION)
  • TABLE 218. BRICS DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 219. BRICS DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 220. BRICS DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 221. BRICS DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 222. G7 DRUG & GENE DELIVERY DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 223. G7 DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 224. G7 DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 225. G7 DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 226. G7 DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY BIOLOGIC, 2018-2032 (USD MILLION)
  • TABLE 227. G7 DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 228. G7 DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY NON VIRAL, 2018-2032 (USD MILLION)
  • TABLE 229. G7 DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 230. G7 DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 231. G7 DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 232. G7 DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 233. NATO DRUG & GENE DELIVERY DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 234. NATO DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 235. NATO DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 236. NATO DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 237. NATO DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY BIOLOGIC, 2018-2032 (USD MILLION)
  • TABLE 238. NATO DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 239. NATO DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY NON VIRAL, 2018-2032 (USD MILLION)
  • TABLE 240. NATO DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 241. NATO DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 242. NATO DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 243. NATO DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 244. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 245. UNITED STATES DRUG & GENE DELIVERY DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 246. UNITED STATES DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 247. UNITED STATES DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 248. UNITED STATES DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 249. UNITED STATES DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY BIOLOGIC, 2018-2032 (USD MILLION)
  • TABLE 250. UNITED STATES DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 251. UNITED STATES DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY NON VIRAL, 2018-2032 (USD MILLION)
  • TABLE 252. UNITED STATES DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 253. UNITED STATES DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 254. UNITED STATES DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 255. UNITED STATES DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 256. CANADA DRUG & GENE DELIVERY DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 257. CANADA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 258. CANADA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 259. CANADA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 260. CANADA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY BIOLOGIC, 2018-2032 (USD MILLION)
  • TABLE 261. CANADA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 262. CANADA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY NON VIRAL, 2018-2032 (USD MILLION)
  • TABLE 263. CANADA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 264. CANADA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 265. CANADA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 266. CANADA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 267. MEXICO DRUG & GENE DELIVERY DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 268. MEXICO DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 269. MEXICO DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 270. MEXICO DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 271. MEXICO DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY BIOLOGIC, 2018-2032 (USD MILLION)
  • TABLE 272. MEXICO DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 273. MEXICO DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY NON VIRAL, 2018-2032 (USD MILLION)
  • TABLE 274. MEXICO DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 275. MEXICO DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 276. MEXICO DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 277. MEXICO DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 278. BRAZIL DRUG & GENE DELIVERY DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 279. BRAZIL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 280. BRAZIL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 281. BRAZIL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 282. BRAZIL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY BIOLOGIC, 2018-2032 (USD MILLION)
  • TABLE 283. BRAZIL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 284. BRAZIL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY NON VIRAL, 2018-2032 (USD MILLION)
  • TABLE 285. BRAZIL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 286. BRAZIL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 287. BRAZIL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 288. BRAZIL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 289. UNITED KINGDOM DRUG & GENE DELIVERY DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 290. UNITED KINGDOM DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 291. UNITED KINGDOM DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 292. UNITED KINGDOM DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 293. UNITED KINGDOM DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY BIOLOGIC, 2018-2032 (USD MILLION)
  • TABLE 294. UNITED KINGDOM DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 295. UNITED KINGDOM DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY NON VIRAL, 2018-2032 (USD MILLION)
  • TABLE 296. UNITED KINGDOM DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 297. UNITED KINGDOM DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 298. UNITED KINGDOM DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 299. UNITED KINGDOM DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 300. GERMANY DRUG & GENE DELIVERY DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 301. GERMANY DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 302. GERMANY DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 303. GERMANY DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 304. GERMANY DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY BIOLOGIC, 2018-2032 (USD MILLION)
  • TABLE 305. GERMANY DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 306. GERMANY DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY NON VIRAL, 2018-2032 (USD MILLION)
  • TABLE 307. GERMANY DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 308. GERMANY DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 309. GERMANY DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 310. GERMANY DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 311. FRANCE DRUG & GENE DELIVERY DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 312. FRANCE DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 313. FRANCE DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 314. FRANCE DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 315. FRANCE DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY BIOLOGIC, 2018-2032 (USD MILLION)
  • TABLE 316. FRANCE DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 317. FRANCE DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY NON VIRAL, 2018-2032 (USD MILLION)
  • TABLE 318. FRANCE DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 319. FRANCE DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 320. FRANCE DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 321. FRANCE DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 322. RUSSIA DRUG & GENE DELIVERY DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 323. RUSSIA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 324. RUSSIA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 325. RUSSIA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 326. RUSSIA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY BIOLOGIC, 2018-2032 (USD MILLION)
  • TABLE 327. RUSSIA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 328. RUSSIA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY NON VIRAL, 2018-2032 (USD MILLION)
  • TABLE 329. RUSSIA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 330. RUSSIA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 331. RUSSIA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 332. RUSSIA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 333. ITALY DRUG & GENE DELIVERY DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 334. ITALY DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 335. ITALY DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 336. ITALY DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 337. ITALY DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY BIOLOGIC, 2018-2032 (USD MILLION)
  • TABLE 338. ITALY DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 339. ITALY DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY NON VIRAL, 2018-2032 (USD MILLION)
  • TABLE 340. ITALY DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 341. ITALY DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 342. ITALY DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 343. ITALY DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 344. SPAIN DRUG & GENE DELIVERY DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 345. SPAIN DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 346. SPAIN DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 347. SPAIN DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 348. SPAIN DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY BIOLOGIC, 2018-2032 (USD MILLION)
  • TABLE 349. SPAIN DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 350. SPAIN